Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Helomics Form Cancer Research Services Partnership

NEW YORK (GenomeWeb) – Indivumed and Helomics announced today that they have partnered to jointly offer products and services for cancer specimen research and clinical data analysis.

The companies said the deal will allow them to offer their customers access to Indivumed's cancer database, biobank, and European research laboratory, as well as Helomics' US-based analytical laboratory services for biospecimen analysis, CLIA testing capabilities, and bioinformatics platform.

Specific terms of the alliance were not disclosed.

The alliance comes less than a year after Pittsburgh-based Helomics completed its restructuring into a clinical contract research and clinical products organization. Hamburg, Germany-based Indivumed, meanwhile, has formed a number of alliances in recent months including ones with MedStar, Intermed, Regeneron, and Northwell Health.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.